SCHEMBL2833334

SCHEMBL2833334

CC(C)(C)OC(=O)NC(C(=O)c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1F)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.44
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
SCN9A Q15858 2/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
PTGES2 Q9H7Z7 4/20 0.36
CTSK P43235 2/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
MCL1 Q07820 2/20 0.35
BCL2 P10415 1/20 0.35
BCL2L1 Q07817 1/20 0.35
SCN5A Q14524 1/20 0.35
RXRA P19793 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833271 0.87 S1PR3 (0.47) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL2834227 0.84 S1PR3 (0.49) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL12096647 0.82 CYP3A4 (0.42) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL12096650 0.82 CYP3A4 (0.42) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL2837634 0.82 CYP3A4 (0.42) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL2837331 0.82 CYP3A4 (0.42) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL2837638 0.82 CYP3A4 (0.42) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL2834826 0.80 AAK1 (0.45) S1PR3MEN1ALDH1A1KMT2A
SCHEMBL2832215 0.79 CYP3A4 (0.46) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL2837175 0.78 CYP3A4 (0.50) S1PR3CYP3A4CYP2D6SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CYP3A4 1043/4885CYP2D6 767/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CYP3A4 1043/4885CYP2D6 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.